Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco is a joint effort from the combined staff of "The Pink Sheet" DAILY and Scrip Intelligence.
J.P. Morgan Notebook Day 3: Regeneron, AstraZeneca CRISPR And Juno
More from Alimentary/Metabolic
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.